Correlation Between Lyra Therapeutics and Cingulate Warrants

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Lyra Therapeutics and Cingulate Warrants at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lyra Therapeutics and Cingulate Warrants into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Lyra Therapeutics and Cingulate Warrants, you can compare the effects of market volatilities on Lyra Therapeutics and Cingulate Warrants and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lyra Therapeutics with a short position of Cingulate Warrants. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lyra Therapeutics and Cingulate Warrants.

Diversification Opportunities for Lyra Therapeutics and Cingulate Warrants

0.38
  Correlation Coefficient

Weak diversification

The 3 months correlation between Lyra and Cingulate is 0.38. Overlapping area represents the amount of risk that can be diversified away by holding Lyra Therapeutics and Cingulate Warrants in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cingulate Warrants and Lyra Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lyra Therapeutics are associated (or correlated) with Cingulate Warrants. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cingulate Warrants has no effect on the direction of Lyra Therapeutics i.e., Lyra Therapeutics and Cingulate Warrants go up and down completely randomly.

Pair Corralation between Lyra Therapeutics and Cingulate Warrants

Given the investment horizon of 90 days Lyra Therapeutics is expected to under-perform the Cingulate Warrants. But the stock apears to be less risky and, when comparing its historical volatility, Lyra Therapeutics is 2.42 times less risky than Cingulate Warrants. The stock trades about -0.05 of its potential returns per unit of risk. The Cingulate Warrants is currently generating about 0.01 of returns per unit of risk over similar time horizon. If you would invest  7.00  in Cingulate Warrants on September 13, 2024 and sell it today you would lose (3.20) from holding Cingulate Warrants or give up 45.71% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy98.44%
ValuesDaily Returns

Lyra Therapeutics  vs.  Cingulate Warrants

 Performance 
       Timeline  
Lyra Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Lyra Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Cingulate Warrants 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Very Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Cingulate Warrants are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly inconsistent technical and fundamental indicators, Cingulate Warrants showed solid returns over the last few months and may actually be approaching a breakup point.

Lyra Therapeutics and Cingulate Warrants Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Lyra Therapeutics and Cingulate Warrants

The main advantage of trading using opposite Lyra Therapeutics and Cingulate Warrants positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lyra Therapeutics position performs unexpectedly, Cingulate Warrants can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cingulate Warrants will offset losses from the drop in Cingulate Warrants' long position.
The idea behind Lyra Therapeutics and Cingulate Warrants pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Other Complementary Tools

Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Transaction History
View history of all your transactions and understand their impact on performance
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments